Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2004

01-01-2004

p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases

Authors: Anand G. Menon, Rob A.E.M. Tollenaar, Cornelis J.H. van de Velde, Hein Putter, Connie M. Janssen-van Rhijn, Rob Keijzer, Gert Jan Fleuren, Peter J.K. Kuppen

Published in: Clinical & Experimental Metastasis | Issue 1/2004

Login to get access
Metadata
Title
p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases
Authors
Anand G. Menon
Rob A.E.M. Tollenaar
Cornelis J.H. van de Velde
Hein Putter
Connie M. Janssen-van Rhijn
Rob Keijzer
Gert Jan Fleuren
Peter J.K. Kuppen
Publication date
01-01-2004
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2004
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/B:CLIN.0000017206.08931.42

Other articles of this Issue 1/2004

Clinical & Experimental Metastasis 1/2004 Go to the issue

OriginalPaper

An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer

OriginalPaper

Measurement of tumor load and distribution in a model of cancer-induced osteolysis: A necessary precaution when testing novel anti-resorptive therapies

OriginalPaper

A systemic antitumor immune response prevents outgrowth of lung tumors after i.v. rechallenge but is not able to prevent growth of experimental liver tumors

OriginalPaper

Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients

OriginalPaper

5-Aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis

OriginalPaper

Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits